Transcript Slide 1

Recombinant DNA Technology
Human insulin monomer
The Principle
DNA
Highly stable and relatively easy to
manipulate.
RNA
Degrades quickly.
Protein
The biologically active material that is
needed. Impossible to synthesize
artificially and difficult (expensive) to purify
from natural sources.
What we can do….
• Precisely detect and amplify very small amounts
of DNA and RNA (just a few copies will work)
• Rapidly determine sequence whether known or
unknown
• Recombine (cut and paste) sequences together
or deliberately change (mutate) them.
• Express genes in virtually any organism at any
level using recombinant DNA plasmids and
viruses
So what is all this good for?
• Biological products can be produced for medical
reasons.
• Organisms can be genetically modified to fit
specific needs.
• Individuals can be rapidly screened for
syndromes, diseases, and side effects.
• Treatment for individuals with genetic
syndromes/diseases
• Crime solving/identification
Microarray
(Genomics)
Gene chips
Screen 13,000 genes at once!
Can be used to rapidly identify disease conditions.
Restriction Mapping
Genetic screening
Forensics
Forensics
1
2
3
FROM
BLOOD
AT CRIME
SCENE
4
5
6
7
Reverse transcription and/or PCR
amplification
GOI or DNA product cut with same
restriction enzyme as vector
Manipulating
DNA
Transcription promoter
Selectable gene
(antibiotic resistance)
Recombinant DNA
products can be produced
in cultured tissue cells
(bioreactors) or in
animals and plants
(“Pharming”)
A Specific Case—Human Insulin
• A large complex
molecule
• Virtually absent in type
1 diabetics
• Originally purified from
bovine or porcine
tissues
• Difficult to purify, low
activity
• Recombinant human
insulin generated in
bacteria.
Transgenics
Animals and
plants can also
be genetically
altered for
desirable
characteristics
such as
herbicide
resistance.
Risks..
Environmental impact
Human health
Fig. 16.13a, p. 263
Gene Therapy
Transgenic humans
Therapeutic potential
Gene Therapy’s Growing Pains
• How do you get the gene where you need it?
– Remove tissue (bone marrow), modify, replace
– Viral vectors (adenovirus and retrovirus vectors)
– Liposomes (lipid spheres)
• How do you get the gene to express correctly?
– Therapy of limited duration (in practice)
• Remember insertional mutagenesis?
– Do no harm!
• Immune rejection and other complications
– First human death from gene therapy in 1999.
Bioethics
• Patient “Informed Consent”
– Do they really understand the risks?
• Can a gene be “owned”?
– How about a modified gene?
• Environmental impact of bioengineering?
• Right to genetic privacy?
• Bioengineering of human beings?